ArticleTherapeutic advances in medical oncology2019
FAM84B promotes prostate tumorigenesis through a network alteration.
Article in Therapeutic advances in medical oncology, 2019. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 12 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
12 citing papers in PubMed, 24 citations in OpenAlex.
- Extrachromosomal circular DNA promotes prostate cancer progression through the FAM84B/CDKN1B/MYC/WWP1 axis.Cellular & molecular biology letters · 2024Article
- Article
- Article
- PCSK9 facilitates melanoma pathogenesis via a network regulating tumor immunity.Journal of experimental & clinical cancer research : CR · 2023Article
- Elevated FAM84B promotes cell proliferation via interacting with NPM1 in esophageal squamous cell carcinoma.Cell death discovery · 2022Article
- MiR-205-5p Functions as a Tumor Suppressor in Gastric Cancer Cells through Downregulating FAM84B.Journal of oncology · 2022Article
- Prognostic and Therapeutic Potential of the OIP5 Network in Papillary Renal Cell Carcinoma.Cancers · 2021Article
- An in vitro vesicle formation assay reveals cargo clients and factors that mediate vesicular trafficking.Proceedings of the National Academy of Sciences of the United States of America · 2021Article
- Article
- Article
- Article
- The Oncogenic Potential of the Centromeric Border Protein FAM84B of the 8q24.21 Gene Desert.Genes · 2020Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
10 authors at 5 institutions in 3 countries.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundThe aim of this study was to investigate the contributions of FAM84B in prostate tumorigenesis and progression.
methodsA FAM84B mutant with deletion of its HRASLS domain (ΔHRASLS) was constructed. DU145 prostate cancer (PC) cells stably expressing an empty vector (EV), FAM84B, or FAM84B (ΔHRASLS) were produced. These lines were examined for proliferation, invasion, and growth in soft agar
resultsFAM84B but not FAM84B (ΔHRASLS) increased DU145 cell invasion and growth in soft agar. Co-immunoprecipitation and co-localization analyses revealed an interaction between FAM84B and FAM84B (ΔHRASLS), suggesting an intramolecular association among FAM84B molecules. FAM84B significantly enhanced DU145 cell-derived xenografts and lung metastasis. In comparison with DU145 EV cell-produced tumors, those generated by DU145 FAM84B cells showed a large number of differentially expressed genes (DEGs;
conclusionsFAM84B promotes prostate tumorigenesis through a complex network that predicts PC recurrence.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.